Fedratinib (Inrebic) is a kinase inhibitor. It is indicated for the treatment of adult patients with intermediate- or high-risk primary myelofibrosis, or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia). As a prescription drug, extra caution is required regarding its purchase channels, medication safety, and authenticity verification.
How to Purchase Fedratinib (Inrebic)
Overseas Purchase
Patients may choose to consult and purchase the medication at hospital pharmacies or regular drugstores in countries or regions where fedratinib has been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budgets and plans in advance before purchasing.
Purchase through Medical Service Institutions
Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions can usually provide legal import channels and offer professional consultation and guidance.
Precautions for Purchasing Fedratinib (Inrebic)
Prescription and Medication Supervision
The standard dose of fedratinib is 400mg taken orally once daily (for patients with a baseline platelet count ≥ 50×10⁹/L).
Doctors will adjust the dose based on the patient’s response; in case of adverse reactions, it may be necessary to interrupt administration, reduce the dose, or discontinue the drug permanently.
During the medication period, regular monitoring of complete blood count, liver function, amylase, lipase and other indicators is required.
Medication Warnings for Special Populations
Patients with Hepatic Impairment: Enhanced monitoring of liver function is required.
Patients with Renal Impairment: For patients with severe renal impairment (CLcr 15-29mL/min), the dose needs to be reduced to 200mg taken once daily.
Pregnant and Lactating Women: The drug has embryo-fetal toxicity. Women of childbearing age need to take effective contraceptive measures until 1 month after stopping the drug, and breastfeeding is prohibited during treatment.
Elderly Patients: Patients over 65 years old may have a higher incidence of adverse reactions.
Management of Drug Interactions
Avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin).
When used in combination with drugs that are substrates of CYP3A4, CYP2C19, or CYP2D6, dose adjustment is required.
Methods for Authenticating Fedratinib (Inrebic)
Verification of Packaging Characteristics
Size 0 reddish-brown opaque capsules.
The cap is printed with "FEDR 100mg" in white.
The bottle packaging specification is 120 capsules per bottle.
Verification of Drug Information
Import Drug Registration Certificate number.
Production batch number and expiration date.
Manufacturer information (Bristol-Myers Squibb Company).
